ASND stock icon

Ascendis Pharma
ASND

$136.32
0.82%

Market Cap: 7.79B

 

About: Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates in North America, China, and Europe and derives the majority of its revenue from North America.

Employees: 879

0
Funds holding %
of 6,702 funds
0
Analysts bullish %
of 15 analysts
News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

49% more repeat investments, than reductions

Existing positions increased: 73 | Existing positions reduced: 49

21% more capital invested

Capital invested by funds: $7.58B [Q4 2023] → $9.17B (+$1.59B) [Q1 2024]

2% more funds holding

Funds holding: 182 [Q4 2023] → 185 (+3) [Q1 2024]

9% more first-time investments, than exits

New positions opened: 38 | Existing positions closed: 35

0% more funds holding in top 10

Funds holding in top 10: 16 [Q4 2023] → 16 (+0) [Q1 2024]

0.18% less ownership

Funds ownership: 105.31% [Q4 2023] → 105.13% (-0.18%) [Q1 2024]

7% less call options, than puts

Call options by funds: $48.3M | Put options by funds: $51.8M

Research analyst outlook

15 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$116
15%
downside
Avg. target
$184
35%
upside
High target
$262
92%
upside

15 analyst ratings

13 positive
87%
neutral
13%
negative
0%
TD Cowen
Yaron Werber
28%upside
$175
Buy
Upgraded
25 Jun 2024
Stifel
Alex Thompson
47%upside
$200
Buy
Initiated
31 May 2024
Morgan Stanley
Vikram Purohit
3%upside
$140
Equal-Weight
Maintained
16 May 2024
Cantor Fitzgerald
Li Watsek
27%upside
$173
Overweight
Reiterated
15 May 2024
Wells Fargo
Derek Archila
92%upside
$262
Overweight
Maintained
3 May 2024

Financial journalist opinion